Copyright
©The Author(s) 2005.
World J Gastroenterol. Sep 14, 2005; 11(34): 5342-5346
Published online Sep 14, 2005. doi: 10.3748/wjg.v11.i34.5342
Published online Sep 14, 2005. doi: 10.3748/wjg.v11.i34.5342
All patients | Group A(non-responder) | Group B(relapser) | |
Male (%) | 70 | 80.5 | 59 |
Mean age | 40.4 | 39.6 | 41.8 |
Genotype 1 (%) | 70 | 75 | 57 |
Serum ALT (U/L) | 70 ± 2 | 67 ± 6 | 75 ± 10 |
Viral load1 (%) | |||
< 2 Mio copies/mL | 37 | 39 | 35 |
> 2 Mio copies/mL | 63 | 61 | 65 |
HAI score2 (%) | |||
HAI score (0-1) | 72 | 68 | 77 |
HAI score (3-4) | 28 | 32 | 23 |
- Citation: Hass HG, Kreysel C, Fischinger J, Menzel J, Kaiser S. High-dose interferon-α2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-α monotherapy. World J Gastroenterol 2005; 11(34): 5342-5346
- URL: https://www.wjgnet.com/1007-9327/full/v11/i34/5342.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i34.5342